HIV-associated neurocognitive disorders

Currently, neuropsychological impairment among HIV+ patients on antiretroviral therapy leads to a reduction in the quality of life and it is an important challenge due to the high prevalence of HIV-associated neurocognitive disorders and its concomitant consequences in relation to morbidity and mortality- including those HIV+ patients with adequate immunological and virological status. The fact that the virus is established in CNS in the early stages and its persistence within the CNS can help us to understand HIV-related brain injury even when highly active antiretroviral therapy is effective. The rising interest in HIV associated neurocognitive disorders has let to development new diagnostic tools, improvement of the neuropsychological tests, and the use of new biomarkers and new neuroimaging techniques that can help the diagnosis. Standardization and homogenization of neurocognitive tests as well as normalizing and simplification of easily accessible tools that can identify patients with increased risk of cognitive impairment represent an urgent requirement. Future efforts should also focus on diagnostic keys and searching for useful strategies in order to decrease HIV neurotoxicity within the CNS.

[1]  J. Becker,et al.  Dementia in AIDS patients , 1993, Neurology.

[2]  A. Ardila,et al.  HUMANS: An English and Spanish Neuropsychological Test Battery for Assessing HIV-1-Infected Individuals—Initial Report , 2004, Applied neuropsychology.

[3]  L. Pulliam,et al.  Differential Cognitive Impairment in HCV Coinfected Men With Controlled HIV Compared to HCV Monoinfection , 2013, Journal of acquired immune deficiency syndromes.

[4]  H. Amièva,et al.  Cognitive disorders in HIV-infected patients: are they HIV-related? , 2013, AIDS.

[5]  K. Blennow,et al.  CSF amyloid β42 and tau levels correlate with AIDS dementia complex , 2005, Neurology.

[6]  Jeannette R. Mahoney,et al.  Cognitive reserve protects against apathy in individuals with human immunodeficiency virus. , 2014, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[7]  P. Vernazza,et al.  Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid , 2013, Journal of acquired immune deficiency syndromes.

[8]  Jean-Marie Annoni,et al.  Cognitive dysfunction in HIV patients despite long-standing suppression of viremia , 2009, AIDS.

[9]  Renaud Richard,et al.  Diccionario de hispanoamericanismos : no recogidos por la Real Academia (formas homónimas, polisémicas y otras derivaciones morfosemánticas) , 2006 .

[10]  B. Clotet,et al.  A Brief and Feasible Paper-Based Method to Screen for Neurocognitive Impairment in HIV-Infected Patients: The NEU Screen , 2013, Journal of acquired immune deficiency syndromes.

[11]  C. Power,et al.  Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy , 2009, HIV medicine.

[12]  Winnie S. Liang,et al.  GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. , 2007, Neuron.

[13]  J. Becker,et al.  Updated research nosology for HIV-associated neurocognitive disorders , 2007, Neurology.

[14]  K. Robertson,et al.  Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents , 2009, AIDS.

[15]  I. Grant,et al.  Initial Validation of a Screening Battery for the Detection of HIV-Associated Cognitive Impairment , 2004, The Clinical neuropsychologist.

[16]  I. Grant,et al.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. , 2008, Archives of neurology.

[17]  J T Becker,et al.  Biomarkers of HIV-1 CNS infection and injury , 2007, Neurology.

[18]  J. Thome.  Journal of Molecular Psychiatry , 2013, Journal of molecular psychiatry.

[19]  L. Ene,et al.  How much do antiretroviral drugs penetrate into the central nervous system? , 2011, Journal of medicine and life.

[20]  Jianhui Zhong,et al.  Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment , 2011, AIDS.

[21]  P. Maruff,et al.  HIV and age do not substantially interact in HIV-associated neurocognitive impairment. , 2011, The Journal of neuropsychiatry and clinical neurosciences.

[22]  M. Silveri,et al.  Cardiovascular risk factors and carotid intima‐media thickness are associated with lower cognitive performance in HIV‐infected patients , 2013, HIV medicine.

[23]  I. Grant,et al.  Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders , 2004, Annals of neurology.

[24]  Monica Rosselli,et al.  Neuropsychological characteristics of normal aging , 1989 .

[25]  Terry L. Jernigan,et al.  HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors , 2010, Journal of NeuroVirology.

[26]  M. Kivipelto,et al.  Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment. , 2010, Biochemical Society transactions.

[27]  K. Mayer.  Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  R. Echemendia.  Cultural Diversity and Neuropsychology: An Uneasy Relationship in a Time of Change , 2004, Applied neuropsychology.

[29]  I. Grant,et al.  Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder , 2012, Neurology.

[30]  D. Fuchs,et al.  Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. , 2007, The Journal of infectious diseases.

[31]  O. Selnes,et al.  The International HIV Dementia Scale: a new rapid screening test for HIV dementia , 2005, AIDS.

[32]  S. Lipton,et al.  Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study , 2007, AIDS.

[33]  J. Billard,et al.  Mechanisms underlying the neuroprotective effect of brain reserve against late life depression , 2015, Journal of Neural Transmission.

[34]  M. Gill,et al.  Neurologic disease burden in treated HIV/AIDS predicts survival , 2010, Neurology.

[35]  C. Hinkin,et al.  The aggregate effects of multiple comorbid risk factors on cognition among HIV-infected individuals , 2013, Journal of clinical and experimental neuropsychology.

[36]  R. Ownby,et al.  Neurocognition, health-related reading literacy, and numeracy in medication management for HIV infection. , 2010, AIDS patient care and STDs.

[37]  Justin C McArthur,et al.  The prevalence and incidence of neurocognitive impairment in the HAART era , 2007, AIDS.

[38]  D. Clifford,et al.  Minocycline treatment for HIV-associated cognitive impairment , 2011, Neurology.

[39]  O. Forlenza,et al.  Diagnosis and biomarkers of predementia in Alzheimer's disease , 2010, BMC medicine.

[40]  R. Price,et al.  Cerebrospinal Fluid HIV-1 Infection Usually Responds Well to Antiretroviral Treatment , 2005, Antiviral therapy.

[41]  A Antinori,et al.  Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART , 2004, International journal of STD & AIDS.

[42]  A. Nath,et al.  Synaptic Transport of Human Immunodeficiency Virus-Tat Protein Causes Neurotoxicity and Gliosis in Rat Brain , 2003, The Journal of Neuroscience.

[43]  G. Arendt,et al.  Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration , 2013, European journal of neurology.

[44]  B. Brew,et al.  Biomarkers of HIV related central nervous system disease , 2008, International review of psychiatry.

[45]  Y. Hutin,et al.  Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates , 2003, BMJ : British Medical Journal.

[46]  Melina V Jones,et al.  Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: Protection by memantine , 2000, Annals of neurology.

[47]  I. Grant,et al.  A neuropsychological investigation of multitasking in HIV infection: implications for everyday functioning. , 2011, Neuropsychology.

[48]  Jodie B. Ullman,et al.  Aging, neurocognition, and medication adherence in HIV infection. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[49]  P. Maruff,et al.  The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. , 2006, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[50]  Maria Flora Salvatori,et al.  Persistence of Neuropsychologic Deficits Despite Long-TermHighlyActiveAntiretroviralTherapyinPatients With HIV-Related Neurocognitive Impairment: Prevalence and Risk Factors , 2007, Journal of acquired immune deficiency syndromes.

[51]  A. Ardila,et al.  The future of neuropsychology with Hispanic populations in the United States. , 1999, Archives of Clinical Neuropsychology.

[52]  E. Miller,et al.  Neurologic disorders incidence in HIV+ vs HIV− men , 2012, Neurology.

[53]  S Spudich,et al.  HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. , 2012, Cold Spring Harbor perspectives in medicine.

[54]  O. Selnes,et al.  HIV Dementia Scale: a rapid screening test. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[55]  Andrew J. Saykin,et al.  Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus‐type 1 (HIV‐1) infection , 1991, Neurology.

[56]  A. Ardila-Ardila,et al.  HUMANS: una batería neuropsicológica para la evaluación de pacientes infectados con VIH-1 , 2003 .

[57]  M. R. D. Apodaca,et al.  Quejas cognitivas en personas con infeccion por el virus de la inmunodeficiencia humana en Espana: prevalencia y variables relacionadas , 2014 .

[58]  Michael J. Taylor,et al.  HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy , 2010, Neurology.

[59]  K. Harding,et al.  HIV-associated neurocognitive disorders , 2015, Journal of Neurology.

[60]  D. Galasko,et al.  Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans , 1998, Neuroscience Letters.

[61]  F. Scaravilli,et al.  The Changing Pattern of HIV Neuropathology in the HAART Era , 2003, Journal of neuropathology and experimental neurology.

[62]  S. Letendre.  Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. , 2011, Topics in antiviral medicine.

[63]  Winnie S. Liang,et al.  GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers , 2007, Neuron.

[64]  Y. Liu,et al.  Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort , 2004, Journal of Neuroimmunology.

[65]  C. Hinkin,et al.  Neuropsychological aspects of coinfection with HIV and hepatitis C virus. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  L. Eberly,et al.  Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons , 2013, Neurology.

[67]  Michael J. Taylor,et al.  Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort , 2011, AIDS.

[68]  K. Marder,et al.  An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. , 2007, Archives of neurology.

[69]  P. Narciso,et al.  Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. , 2005, AIDS research and human retroviruses.

[70]  O. Selnes,et al.  Higher frequency of dementia in older HIV-1 individuals , 2004, Neurology.

[71]  S. Rourke,et al.  Employment status is associated with both physical and mental health quality of life in people living with HIV , 2011, AIDS care.

[72]  B. Brew.  Markers of AIDS dementia complex: the role of cerebrospinal fluid assays. , 2001, AIDS.

[73]  F. Vaida,et al.  Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders , 2013, Journal of NeuroVirology.

[74]  G. Marín,et al.  Research with Hispanic Populations , 1991 .

[75]  Jintanat Ananworanich,et al.  Central nervous system viral invasion and inflammation during acute HIV infection. , 2012, The Journal of infectious diseases.

[76]  L. Koski,et al.  Computerized testing augments pencil‐and‐paper tasks in measuring HIV‐associated mild cognitive impairment * , 2011, HIV medicine.

[77]  I. Grant,et al.  Cognitive Neuropsychology of HIV-Associated Neurocognitive Disorders , 2009, Neuropsychology Review.

[78]  C. Hinkin,et al.  Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse , 2004, AIDS.

[79]  J. Kaldor,et al.  Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. , 1999, AIDS.

[80]  Francisco González-Scarano,et al.  The neuropathogenesis of AIDS , 2005, Nature Reviews Immunology.

[81]  Grupo de Estudio del Sida.  [Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders]. , 2014, Enfermedades infecciosas y microbiologia clinica.

[82]  D. Fuchs,et al.  HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. , 2010, The Journal of infectious diseases.

[83]  T. Marcotte,et al.  Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature , 2013, AIDS.

[84]  Bruce J Brew,et al.  Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy , 2003, AIDS.